Article Abstract

Targeting glioblastoma stem-cells: a recurrent challenge in neurooncology

Authors: Giulia Berzero, Alberto Picca, Marc Sanson

Abstract

Glioblastoma (GBM) is the most common and most aggressive primary brain tumor in adults. To date, this tumor remains rapidly fatal despite treatment, median overall survival not exceeding 15 months from diagnosis (1).